Serum Markers and Lymphocyte Response to IL-2 Therapy
Author Information
Author(s): Fumagalli L, Lissoni P, Felice G Di, Meregalli S, Valsuani G, Mengo S, Rovelli F
Primary Institution: Chiron Italia, Milano, Italy
Hypothesis
The study aims to analyze the relationship between pretreatment circulating values of certain markers and the changes in lymphocyte number in response to IL-2 administration.
Conclusion
High pretreatment levels of inflammatory markers negatively affect the response to IL-2 therapy in cancer patients.
Supporting Evidence
- Lymphocytosis is a marker of IL-2 therapy efficacy.
- High pretreatment values of IL-6, neopterin, and sIL-2R were found in many patients.
- Patients with normal pretreatment values had better responses to IL-2 therapy.
Takeaway
Doctors found that if patients had high levels of certain markers before treatment, their bodies didn't respond well to the medicine that helps fight cancer.
Methodology
Twenty metastatic renal cell cancer patients were treated with subcutaneous IL-2 immunotherapy and their responses were analyzed based on pretreatment serum markers.
Limitations
Further studies are needed to confirm the impact of pretreatment immune status on overall survival and quality of life.
Participant Demographics
Patients with metastatic renal cell cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website